Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme - Wikidata - wikimedia - TriplyDB

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme

http://www.wikidata.org/entity/Q37718203

about

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications Patient-derived xenografts: a relevant preclinical model for drug development BAP31, a promising target for the immunotherapy of malignant melanomas.YY1 regulates melanoma tumorigenesis through a miR-9 ~ RYBP axis Survival of melanoma patients treated with novel drugs: retrospective analysis of real-world data.Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.New derivatives of the antimalarial drug Pyrimethamine in the control of melanoma tumor growth: an in vitro and in vivo study.Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients.New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors.Cancer Immunotherapies: Are They as Effective in the Elderly?Checkpoint inhibition and melanoma: Considerations in treating the older adult.Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials Ipilimumab in melanoma.Immunosenescence: limitations of natural killer cell-based cancer immunotherapy.Immunosenescence and cancer.What have we learned from cancer immunotherapy in the last 3 years?Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations.Skin Cancer Epidemics in the Elderly as An Emerging Issue in Geriatric Oncology Predictors of response and resistance to checkpoint inhibitors in solid tumors.Immune-related tumor response assessment criteria: a comprehensive review.Overcoming Barriers of Age to Enhance Efficacy of Cancer Immunotherapy: The Clout of the Extracellular Matrix.Current status and perspectives in immunotherapy for metastatic melanoma.Immune checkpoint inhibitors in melanoma

P2860

Q26996518-009DF10F-8D65-4240-B7E6-6551360F67C4 Q28067191-D48FE786-C645-4CA1-A8A8-199309765813 Q35518667-9000C154-5170-4E47-BEDD-767D5E9D5551 Q35879952-0B32A835-00E5-4433-AF53-EE6016E0246B Q36400145-24B74C28-821F-4A66-A93C-788CB668EF60 Q37091138-F032B984-7FFC-40FD-A507-37DA8FFF96AB Q37237139-C26E8956-D569-4018-8BE5-CA79C1B9FDEE Q38600760-71072F21-2412-4189-B24D-8156DEB609F6 Q38632728-47A1000E-6D25-4DE3-8B65-6F3CDE040A61 Q38679662-EA793945-E765-46BF-9034-932303A8916D Q38785125-A4CDE416-4F0C-4A87-B774-55D09AB7354A Q38831830-385CDD04-BB35-4023-A8B6-F707BEA798E3 Q38893697-AFDA1507-9AFB-40F0-9763-1CEA78988EF8 Q38928938-26CD28B0-E757-4CF7-9908-E025E4B132FC Q39144853-6B3685B2-80DA-4549-A459-0092E76E33D1 Q40065733-98218CD6-0B49-4CC8-9377-C7F2D66681D7 Q41064873-E68C30FF-0AA0-4E8E-8B2C-614729FA6392 Q41952060-8C4FF1FE-0024-40D9-B849-01DF72058FD2 Q47150557-6691A0C1-5EC4-4D95-8086-024644818B82 Q49668388-86CDABFF-6886-47F4-88EF-1B9BBD1F2288 Q51762655-380FE81C-55EF-4E9D-A642-EF0CB6452B7E Q54574397-CE57D1ED-37FA-4E0B-ACC9-ED439219E80F Q56895914-483DBEB1-9BDE-4E40-A3F3-CEBDDAB480E9

P2860

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme

http://www.wikidata.org/entity/Q37718203

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 April 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Efficacy and safety of ipilimu ...... the expanded access programme

@en

Efficacy and safety of ipilimu ...... the expanded access programme.

@nl

type

label

Efficacy and safety of ipilimu ...... the expanded access programme

@en

Efficacy and safety of ipilimu ...... the expanded access programme.

@nl

prefLabel

Efficacy and safety of ipilimu ...... the expanded access programme

@en

Efficacy and safety of ipilimu ...... the expanded access programme.

@nl

P1433

Q37718203-54E2D3D5-6F4A-4C8E-A4B0-2CC9343B377A

P1476

Q37718203-A0E67A51-B352-4547-9224-BDC6909F8BB7

P2093

Q37718203-0063552B-4F44-4000-A455-D8C9837D6BD8

Q37718203-2C06079F-8846-467E-9B60-638E04CF1279

Q37718203-2EC9BA9E-AA06-4E42-BA18-B09B33B30FE6

Q37718203-355A9B20-427B-4B23-B60D-0E42D09F4CA9

Q37718203-3C2FEA7B-82CB-498D-9EEE-B2FFE9B6E0A4

Q37718203-4C6E64E8-EB5E-486F-8CE0-D6DEEE582E94

Q37718203-67CB369E-7E9C-481F-9F29-21B6D4C47432

Q37718203-7C2EE24E-DA22-4AB9-A6DF-24892CF949E2

Q37718203-9C0A8B9C-A62B-4529-AEDB-F4D38D611D77

Q37718203-C0E1202F-6C36-4E5D-9697-36EA7F1FFD32

P2860

Q37718203-06827C32-4282-4447-ABC8-547B01F4DB50

Q37718203-0EE6BB48-E721-4E43-8A50-9B45A8BB00E2

Q37718203-1CA8570D-7191-49FB-8C9D-912062688160

Q37718203-225C0565-CE5D-476D-AB20-BA070153C6C4

Q37718203-47ED7196-ACDA-443B-A60F-9267C8AEE5D1

Q37718203-4E3A1638-FA0B-4261-BD4B-29D279EB9340

Q37718203-4F18EA7B-FF48-4843-A827-B253D7DC369C

Q37718203-5DC3EFE1-612E-47C7-9957-D7B686574485

Q37718203-5F74732A-7708-4246-98BB-47D63026F35D

Q37718203-69D0A71C-8C13-46DE-B5AD-336CEAC0AB09

P2888

Q37718203-8DF97617-6152-4FB1-AA00-17571419EBA7

P304

Q37718203-014FCD04-EFB5-46B6-8A38-68F07EE9622B

P31

Q37718203-BAC9F378-5BB0-464A-AE0B-0DBCBE8F4E3E

P356

Q37718203-928B125A-F6DD-42C8-AD62-CCDC9B5DD35D

P478

Q37718203-27050A75-4397-4974-9A60-8E5C75244593

P50

Q37718203-2C5253F9-4824-46D6-9E8E-53C674312772

Q37718203-30ECFEB1-EF6C-4007-9D0F-F02C73674982

Q37718203-52786C4B-E056-4C20-A5B5-23BBE4DE691D

Q37718203-7F7EDBC5-5320-49AD-8541-760B7881452E

Q37718203-8ED97D44-284E-4D8B-9665-68F7DB7292B3

Q37718203-907F8626-F3D4-4ABE-A8FA-B114B3CDEDC3

Q37718203-A96119DC-E31E-4294-A9A4-09A3CCFF6312

Q37718203-AAA861D3-8164-4A27-9B78-F740E175116E

Q37718203-D54F1431-6FE4-40E0-B684-10CD9D25A435

Q37718203-FB6C76E4-529E-4588-A1E8-6AE809CD0F02

P577

Q37718203-32C7FFD7-843C-4FF5-A0B1-5041441D2E14

P5875

Q37718203-5A2CADFE-2AF1-43C0-9595-89C78A3DB174

P6179

Q37718203-F9F3DC19-720F-4DD5-8AFE-7657CABD68AD

P698

Q37718203-26AF7670-0F4C-474E-A63E-A6D7C746245C

P921

Q37718203-41D65CFE-EA36-417D-A50D-2598008A01FA

Q37718203-852F4CF7-3E95-4E4F-A0EB-558A0AD9C5CE

P932

Q37718203-424D0F9B-D7A8-4CFB-90DC-CA26D26C5DE5

P356

1756-9966-33-30

P1433

Journal of Experimental & Clinical Cancer Research

P1476

Efficacy and safety of ipilimu ...... the expanded access programme

@en

P2093

Barbara Merelli

http://www.w3.org/2001/XMLSchema#string

Carmen Nuzzo

http://www.w3.org/2001/XMLSchema#string

Emilia Cocorocchio

http://www.w3.org/2001/XMLSchema#string

Francesco de Rosa

http://www.w3.org/2001/XMLSchema#string

Gaetana Rinaldi

http://www.w3.org/2001/XMLSchema#string

Giorgio Parmiani

http://www.w3.org/2001/XMLSchema#string

Marco Grosso

http://www.w3.org/2001/XMLSchema#string

Maria Grazia Bernengo

http://www.w3.org/2001/XMLSchema#string

Paolo Antonio Ascierto

http://www.w3.org/2001/XMLSchema#string

Riccardo Marconcini

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2010

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Final version of 2009 AJCC melanoma staging and classification

Geriatric oncology: challenges for the new century.

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.

Malignant melanoma in the elderly: different regional disease and poorer prognosis.

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.

P2888

1756-9966-33-30

P304

30

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1756-9966-33-30

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Paolo Marchetti

Lorenza Di Guardo

Antonio M Grimaldi

V Chiarion-Sileni

Alessandro Testori

P577

2014-04-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261442351

http://www.w3.org/2001/XMLSchema#string

P6179

1023400666

http://www.w3.org/2001/XMLSchema#string

P698

24708900

http://www.w3.org/2001/XMLSchema#string

P921

P932

3996509

http://www.w3.org/2001/XMLSchema#string